Assuming a preferential central action of GLP1/E, we conducted label-free, quantitative proteomic analyses in the hypothalamus of the two models of PCOS, after chronic treatment with the di-agonist, as a means to disclose putative pathways for the metabolic actions of the di-agonist, and the basis for the partially differential responses between the two models of PCOS, which diverge also in terms of phenotypic presentation
In September 2019, Rybelsus, the first and only oral GLP-1 analog was approved by the U.S.FDA for improving the glycemic control in type-2 diabetes patients
Single nucleotide polymorphisms and microsatellites in the canine glutathione S-transferase pi 1 (GSTP1) gene promoter
Studies on Dipeptidyl(Amino)Peptidase IV (Glycyl-Proline Naphthylamidase)
These 7 food swaps add protein, cut empty calories, and improve nutrition without overhauling your diet or learning new recipes